ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

DWP212525

A development code. Also written as “DWP212525 XXmg”.

Its studies are mostly in Autoimmune Diseases, led by Daewoong Pharmaceutical.

Furthest: phase 1, since Dec 6, 20241 company-led study, 1 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daewoong Pharmaceutical11 open or runningphase 1since Dec 6, 2024Dec 6, 2024Dec 30, 2026phase 1 · NCT06736587

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 6, 2024First study: phase 1 study in Autoimmune DiseasesFirst studyNCT06736587 · 84 planned · South Korea

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Autoimmune DiseasesNCT06736587

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06736587Autoimmune Diseases · South Korea1RecruitingDec 30, 202684

How it is read

Names in the registry

  • “DWP212525 XXmg”, 1 entry

Codes read as this program: DWP212525.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.